Best treatment for multiple sclerosis may be antivirals
Reported byNew Scientist ↗·Sourced by Goodlede
Research by Harvard Medical School and Harvard T.H. Chan School of Public Health found that people with multiple sclerosis produce twice as many CD4 T-cells targeting actively replicating Epstein-Barr virus compared to people without the condition, suggesting antiviral drugs targeting EBV could be as effective as immune-suppressing drugs but with fewer side effects.
The approach is promising but not yet clinically available; pharmaceutical companies have been called to develop such antivirals.
Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.
Read the full story at New Scientist
Read original story ↗More good news, verified daily.
Goodlede covers positive developments across science, nature, rights, and human achievement — verified before they appear. No hype, no roundups, no PR wires.
© 2026 Wag Media, LLC
More from Goodlede